Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06025877 · ClinicalTrials.gov registry record

Quality Improvement and Clinical Utility PrecivityAD2(TM) Clinician Survey

A clinical trial of Alzheimer Disease and Mild Cognitive Impairment, sponsored by C2N Diagnostics.

Active
Registry status
400
Enrollment target
9
Study locations

NCT06025877 is a study of Alzheimer Disease and Mild Cognitive Impairment that is active but no longer recruiting, run by C2N Diagnostics. The registered enrollment target is 400 participants, below the 2,749-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (85% lower). The trial reports 9 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06025877, a study of Alzheimer Disease and Mild Cognitive Impairment, is active but no longer recruiting, sponsored by C2N Diagnostics.

ACTIVE NOT RECRUITING
Registry status
400 participants
Enrollment target
9
Study locations

Study Summary

There is a major unmet need for timely, non-invasive, and low-burden evaluation of patients presenting with mild cognitive impairment (MCI) and dementia. MCI impacts 12-18% of people in the United States over age 60 years (Alzheimer's Association. Mild Cognitive Impairment (MCI) available at https://www.alz.org/alzheimers-dementia/what-is-dementia/related\_conditions/mild-cognitive-impairment. Accessed August 16, 2022). MCI does not substantially interfere with daily activities, although complex functional tasks may be performed less efficiently (Knopman DS, Petersen RC. Mild cognitive impairment and mild dementia: a clinical perspective. Mayo Clin Proc. 2014;89(10):1452-1459. doi:10.1016/j.mayocp.2014.06.019). Approximately 30% of MCI patients have Alzheimer's disease (AD) as a cause of their symptoms (Lopez,OL, Kuller LH, Becker JT, et al. Incidence of dementia in mild cognitive impairment in the cardiovascular health study cognition study. Arch Neurol. 2007;64(3):416-420.doi:10.1001/archneur.64.3.416)). In contrast, dementia is defined by chronic, acquired loss of two or more cognitive abilities caused by brain disease or injury, often associated with significant interference with the ability to function at work or at usual activities. (Knopman DS, Petersen RC. Mild cognitive impairment and mild dementia: a clinical perspective. Mayo Clin Proc. 2014;89(10):1452-1459. doi:10.1016/j.mayocp.2014.06.019). Approximately 60-80% of dementia patients have AD as a cause of their symptoms (Alzheimer's Association. Mild Cognitive Impairment (MCI) available at https://www.alz.org/alzheimers-dementia/what-is-dementia/related\_conditions/mild-cognitive-impairment. Accessed August 16, 2022).

Conditions Studied

Alzheimer Disease Mild Cognitive Impairment Dementia Cognitive Impairment Cognitive Decline Memory Impairment

Interventions

  • OTHER PrecivityAD2(TM) blood test

Study Locations (9)

California

  • UCSF Memory and Aging Center - San Francisco
  • Pacific Brain Health Center - Santa Monica

Missouri

  • Sharlin Health and Neurology - Ozark
  • C2N Diagnostics - St Louis

Illinois

  • Advocate Memory Center - Park Ridge

Indiana

  • Josephson Wallack Munshower Neurology, P.C. - Indianapolis

Louisiana

  • Tulane Doctors Neurosurgery Clinic - New Orleans

Michigan

  • Memorial Healthcare Institute for Neuroscience - Owosso

South Carolina

  • Palmetto Primary Care Physicians - Summerville

Trial Details

FieldValue
Enrollment Target 400 participants
Start Date 2023-11-15
Est. Completion 2025-04-30

Sponsor

C2N Diagnostics

3 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06025877

The ClinicalTrials.gov registry entry for NCT06025877 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,749-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (85% lower). The listed sponsor is C2N Diagnostics, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 6 conditions, with Alzheimer Disease appearing as the primary indexed condition, and to 1 intervention - of which PrecivityAD2(TM) blood test is the first listed.

NCT06025877 reports 9 study locations spanning 7 distinct geographic areas - top geographies include California, Missouri, Illinois.

Frequently Asked Questions

What is clinical trial NCT06025877 about?

NCT06025877 is a clinical study titled "Quality Improvement and Clinical Utility PrecivityAD2(TM) Clinician Survey". There is a major unmet need for timely, non-invasive, and low-burden evaluation of patients presenting with mild cognitive impairment (MCI) and dementia. MCI impacts 12-18% of people in the United States over age 60 years (Alzheimer's Association. Mild Cognitive Impairment (MCI) available at https:/...

What is the current status of trial NCT06025877?

This trial is currently active not recruiting. The enrollment target is 400 participants. The study started on 2023-11-15. Estimated completion is 2025-04-30.

What conditions does trial NCT06025877 study?

This clinical trial studies the following conditions: Alzheimer Disease, Mild Cognitive Impairment, Dementia, Cognitive Impairment, Cognitive Decline.

What interventions are being tested in trial NCT06025877?

The interventions under investigation include: PrecivityAD2(TM) blood test (OTHER).

Who is sponsoring clinical trial NCT06025877?

This trial is sponsored by C2N Diagnostics, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06025877 being conducted?

This trial has 9 study locations across California, Illinois, Indiana, Louisiana, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Alzheimer Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Alzheimer Disease

All registered trials for this condition

Mild Cognitive Impairment

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.